Repeat PSA Screening for Virulent Prostate Cancer

Description:
 

Reference #: 01136

The University of South Carolina is offering licensing opportunities for an improved method of detecting high-risk prostate cancer that is able to distinguish it form non-virulent cancers as well as other conditions associated with elevated levels of prostate-specific antigens.

Invention Description:

The subject invention uses available repeat prostate-specific antigen (PSA) measures from the NCI-funded Prostate Lung Colorectal and Ovarian Cancer Screening Trial (PLCO) to predict subsequent diagnosis of clinically significant prostate cancer.

Potential Applications:

· Detection of virulent (i.e., high-risk, clinically relevant) prostate cancer using PSA alone or in combination with other screening methods

Advantages and Benefits:

· Distinguishes virulent prostate cancer from other prostate-related conditions that may be associated with elevated PSA concentration in blood

Background:

Prostate cancer is the most common cancer in the United States and the second leading cause of cancer deaths among men. It is generally a lower-risk cancer for which the treatment is often worse than the disease. The increased detection of low-risk prostate cancer based on PSA screenings is the foundation of the controversy that has  led to recommendations against screening.  Essentially, the current problems can be summarized as either over-treatment of indolent, low-risk disease that if left untreated has little chance of harming the patient but whose treatment can cause great harm ranging from infections to incontinence; or under-treating virulent, high-risk disease which is likely to be fatal. This technology is an effective way to detect life-threatening prostate cancer and distinguish it from other conditions associated with elevated PSA.

Patent Information:
Category(s):
Health Sciences
For Information, Contact:
Technology Commercialization
University of South Carolina
technology@sc.edu
Inventors:
James Hebert
Azza Shoaibi
Keywords:
© 2018. All Rights Reserved. Powered by Inteum